Predictive Impact Of Biomarkers On Pcr And Survival After De-Escalated Neoadjuvant T-Dm1 With Or Without Endocrine Therapy (Et) Vs. Trastuzumab+Et In Her2+/Hr+ Early Breast Cancer: Wsg Adapt Tp Trial

N. Harbeck,U. Nitz,M. Christgen,S. Kuemmel,M. Braun, C. M. Biehl,C. Schumacher,W. Malter,B. Aktas,H. Forstbauer,J. Tio,E-M. Grischke,C. Kolberg-Liedtke,S. De Haas, R. J. Deurloo,R. E. Kates,C. Eulenburg Zu,R. Wuerstlein,H. Kreipe,O. Gluz

ANNALS OF ONCOLOGY（2021）

引用 6|浏览2

暂无评分

摘要

HER2+/HR+ EBC is a distinct entity associated with different molecular and clinical features compared to HER2+/HR- EBC. ADAPT TP showed promising pCR rates of 40% after only 4x T-DM1 +/- endocrine therapy (ET) which also corresponded to excellent 5y outcome. Optimal patient selection for de-escalation in HER2+/HR+ EBC is still an unsolved question.

查看译文

关键词

early breast cancer,breast cancer,biomarkers,trastuzumab+et,de-escalated

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要